Systemic marker for monitoring anti-inflammatory and antioxidant actions of therapeutic agents
AssigneeThe Cleveland Clinic Foundation
InventorStanley L. Hazen
Life of this patent
Estimating the term…
Abstract
A diagnostic method of monitoring anti-inflammatory and/or antioxidant actions of therapeutic agents comprises determining the level of at least one systemic marker indicative of inflammation or oxidation in a bodily sample taken from a subject at base line or following administration of the therapeutic agent. The marker includes at least one of MPO activity, MPO mass, select MPO-generated oxidation products, and combinations thereof. The level of the systemic marker is compared with a predetermined value to monitor the anti-inflammatory and/or antioxidant actions of the therapeutic agent.
Claims34
A method of monitoring anti-inflammatory or antioxidant actions or both of a therapeutic agent, said method comprising:
- determining a level of at least one systemic marker indicative of inflammation or oxidation in a bodily sample taken from a subject during or following administration of the therapeutic agent, the systemic marker including at least one of
- MPO activity,
- MPO mass,
- an MPO-generated oxidation product selected from the group consisting of nitrotyrosine, methionine sulphoxide, homocitrulline, and combinations thereof, the bodily sample including at least one of serum, plasma, urine, neutrophils, subpopulation of neutrophils, monocytes or subpopulations monocytes,
- wherein the level of the systemic marker is determined per unit of the bodily sample when the systemic marker is MPO activity or MPO mass or both, and
- comparing the level of the systemic marker in the bodily sample with a predetermined value to monitor the anti-inflammatory or antioxidant actions or both of the therapeutic agent, wherein a decrease in the level of the systemic marker in the bodily sample as compared to the predetermined value indicates that the therapeutic agent provides anti-inflammatory or antioxidant actions or both in the subject.
A method of monitoring anti-inflammatory or antioxidant actions or both of therapeutic agents, said method comprising:
- determining a level of at least one systemic marker indicative of inflammation or oxidation or both in a bodily sample taken from a subject following administration of the therapeutic agent, the systemic marker including at least one of
- MPO activity,
- MPO mass,
- an MPO-generated oxidation product selected from the group consisting of nitrotyrosine, methionine sulphoxide, homocitrulline, and combinations thereof;
- the bodily sample including at least one of serum, plasma, urine, monocytes or neutrophils in-blood,
- wherein the level of the systemic marker is determined per unit of the bodily sample when the systemic marker is MPO activity or MPO mass or both, and
- comparing the level of the systemic marker in the bodily sample with a predetermined value to monitor the anti-inflammatory or antioxidant actions or both of the therapeutic agent, wherein the therapeutic agent is administered to treat disorders where inflammation or oxidative damage or both is linked to pathogenesis of the disorder.
A method of monitoring anti-inflammatory or antioxidant actions or both of a HMG CoA reductase inhibitor, said method comprising:
- determining the level of at least one systemic marker indicative of inflammation or oxidation in a bodily sample taken from a subject following administration of the HMG CoA reductase inhibitor, the systemic marker including at least one of
- MPO activity,
- MPO mass,
- an MPO-generated oxidation product selected from the group consisting of nitrotyrosine, methionine sulphoxide, homocitrulline, and combinations thereof,
- the bodily sample including at least one of serum, plasma, urine, monocytes or neutrophils,
- wherein the level of the systemic marker is determined per unit of the bodily sample when the systemic marker is MPO activity or MPO mass or both, and
- comparing the level of the systemic marker in the bodily sample with a predetermined value to monitor the anti-inflammatory or antioxidant actions or both of the HMG CoA reductase inhibitor, wherein a decrease in the level of the systemic marker in the bodily sample as compared to the predetermined value indicates that the HMG CoA reductase inhibitor provides anti-inflammatory or antioxidant actions or both in the subject.
A method of monitoring whether a therapeutic agent provides an anti-inflammatory or antioxidant effect or both, said method comprising:
- i. determining the level of at least one systemic marker indicative of inflammation or oxidation in a bodily sample of blood, plasma, serum, or urine taken from a subject during or following administration of the therapeutic agent, the systemic marker being nitrotyrosine, homocitrulline, or both,
- ii. comparing the level of the systemic marker in the bodily sample with a predetermined value to monitor the anti-inflammatory or antioxidant actions or both of the therapeutic agent, and
- iii. determining that the therapeutic agent provides the anti-inflammatory or antioxidant effect or both if the level of the systemic marker in the bodily sample is less than the predetermined value.
A method of monitoring anti-inflammatory or antioxidant actions or both of therapeutic agents in a subject having a disease associated with inflammation or oxidation, said method comprising:
- determining the number or percentage of the subject's neutrophils or monocytes that contain elevated levels of MPO activity or MPO mass before administration of the therapeutic agent to the subject;
- determining the number or percentage of the subject's neutrophils or monocytes that contain elevated levels of MPO activity or MPO mass during or following administration of the therapeutic agent to the subject,
- wherein a decrease in the number or percentage of the subject's neutrophils or monocytes that contain elevated levels of WO mass or MPO activity during or following administration of the therapeutic agent to the subject as compared to before administration of the therapeutic agent indicates that the therapeutic agent provides an anti-inflammatory or antioxidant actions or both in the subject.
Dependencies are inferred from the claim text.